How Data from the AHA and C3TN Registries of Cardiogenic Shock can Improve Care of Patients with Cardiogenic Shock

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Grant Support/Research Contract - Abbott; Abiomed; AstraZenca; Amgen; Daiichi-Sankyo/Elil Lilly and Company; Merck/Schering Plough; Pfizer; Regeneron; Roche Diagnostics; Novartis; 4TEEN4</li><li>Consultant Fee/Honoraria/Speaker’s Bureau - Abbott</li><li>Consultant Fee/Honoraria/Speaker's Bureau - Roche Diagnostics</li></ul>